Abstract
Heterotopic ossification is a frequent complication following spinal cord injury with 16 per cent to 53 per cent of patients developing varying degrees of pathologic ossification.
The diphosphonates are known to block the transformation of amorphous calcium phosphate into crystalline hydroxyapatite. Therefore, one of the diphosphonates, disodium etidronate (generic name of disodium ethane-l-hydroxy-l, l-diphosphonate (EHDP) was selected for clinical trials to study the effectiveness of EHDP in preventing heterotopic ossification following spinal cord injury.
In a double-blind, clinical study of 149 spinal cord injury patients, disodium etidronate has proven its effectiveness in the prevention of heterotopic ossification. The extent of heterotopic ossification development as measured by the total heterotopic ossification X-ray grade was significanlty less in EHDP-treated patients compared to placebo-treated patients (P<0·05). For maximal effectiveness, EHDP treatment must be started before the onset of the pathological process initiating the development of heterotopic ossification. Further studies are necessary to determine the optimal time to institute EHDP treatment, length of treatment, and minimal effective dose. EHDP is the first therapeutic agent known to alter the formation of heterotopic ossification after spinal injury and may prove useful in other conditions where heterotopic ossification prevention is clinically indicated.
Similar content being viewed by others
Article PDF
References
Altman, R D, Johnston, C C, Khairi, M R A, Wellman, H N, Serafini, A N & Sankey, R R (1973). Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). New Eng. J. Med. 289, 1379–1384.
Casey, P A, Casey, G, Fleisch, H & Russell, R G G (1972). The effect of polyphloretin phosphate, polyoestradiol phosphate, a diphosphonate and a polyphosphate on calcification induced by dihydrotachysterol in skin, aorta and kidney of rats. Experientia, 28, 137–138.
Fleisch, H A, Russell, R G G, Bisaz, S, Mulhaubauer, R C & Williams, D A (1970). The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur. J. Clinc. Invest. 1, 12–18.
Francis, M D, Flora, L & King, W R (1972). The effects of disodium ethane-l-hydroxy-l, l-diphosphonate on adjuvant induced arthritis in rats. Calcif. Tissue Res. 9, 109.
Francis, M D, Russell, R G G & Fleisch, H (1969). Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science, 165, 1264–1266.
Hardy, A G & Dickson, J W (1963). Pathological ossification in traumatic paraplegia. J. Bone J. Surg. 45B, 76–87.
Khairi, M R A, Johnston, Jr, C C, Altman, R D, Wellman, H N, Serafini, A N & Sankey, R R (1974). Treatment of Paget's disease of bone (osteitis deformans). J. Am. Med. Ass. 230, 562–567.
Michael, W R, King, W R & Wakim, J M (1972). Metabolism of disodium ethane-l-hydroxy-l, l-diphosphonate (disodium etidronate) in the rat, rabbit, dog, and monkey. Toxic. appl. Pharmac. 21, 503–515.
Nicholas, J J (1973). Ectopic bone formation in patients with spinal cord injury. Arch. phys. Med. Rehabil. 54, 354–359.
Recker, R R, Hassing, G S, Lau, J R et al. (1973). The hyperphosphatemic effect of disodium ethane-l-hydroxy-l, l-diphosphonate (EHDP™): renal handling of phosphorus and the renal response to parathyroid hormone. J. Lab. Clin. Med. 81, 258–266.
Rossier, A B (1975). Personal communication.
Rossier, A B, Bussat, P, Infante, F et al. (1973). Current facts on para-osteo-arthropathy (POA). Paraplegia, 11, 36–78.
Russell, R G G, Kislig, A M, Casey, P A & Fleisch, H (1973). The effect of diphosphonates and calcitonin on the chemistry and quantitative history of rat bone. Calc. Tissue Res. 11, 179–195.
Russell, R G G, Smith, R, Preston, C, Walton, R J & Woods, C G (1974). Diphosphonates in Paget's disease. Lancet, i, 894–898.
Stover, S L, Hataway, C J & Zeiger, H E (1975). Heterotopic ossification in spinal cord injured patients. Arch. phys. Med. Rehabil. 56, 199–204.
Stover, S L, Niemann, K M N & Miller, III, J M (1975). Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal cord injury patients. To be submitted for publication.
Venier, L H & Ditunno, Jr, J F (1971). Heterotopic ossification in the paraplegic patient. Arch. phys. Med. Rehabil. 52, 475–479.
Wellman, H N, Anger, R T, Browne, A, Tofe, A, Francis, D, Khairi, R & Johnson, C (1973). Evaluation of bone malignancy with 99mTc-Sn-EHDP compared with Na18F. J. nucl. Med. 14. 464–465.
Wharton, G W & Morgan, T H (1970). Ankylosis in the paralyzed patient. J. Bone J. Surg. 52A, no. 1, 105–112.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stover, S., Hahn, H. & Miller, J. Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury (preliminary report). Spinal Cord 14, 146–156 (1976). https://doi.org/10.1038/sc.1976.25
Issue Date:
DOI: https://doi.org/10.1038/sc.1976.25